Against the backdrop of the rapid advancement in Gene Diagnosis and Treatment, mRNA Vaccines, and Small Nucleic Acid Drugs, core raw materials and key technologies in the upstream industrial chain have become the "critical pathway" for industry development. In this issue, we spotlight a company that has been quietly yet persistently dedicated to this field, possessing strong technological expertise and industrial capabilities—Hefei Huana Biomedical Technology Co. Ltd.

Weekly Premium Pick | Issue 10: The Hidden Champion in the Nucleic Acid Arena — Hefei Huana Biomedical Technology Co. Ltd. 

一、Company Positioning: 

A National Mission-Driven Core Force in the Industry.

Hefei Huana Biomedical Technology Co. Ltd. is the wholly-owned subsidiary of Anhui Okeanos, which has been focusing on providing integrated solutions for R&D, production and marketing of modified-nucleosides, nucleotides, phosphoramidites delivery systems, fluorescent dyes and peptide products in the fields of small nucleic acid drugs, mRNA vaccines, gene therapy, and synthetic biology.

Located in the Hefei Circular Economy Demonstration Park, the company operates a GMP standard modern production base with 60,000 m² total construction area. As a Key supporting unit of "Hefei Gene Center", it is committed to becoming a trusted core raw material supplier for the global nucleic acid industry.

二、R&D Capabilities & Achievements:

 Advancing National Strategies, Building Barriers with Patent.

Since its establishment, the company has experienced rapid growth. Its core products have completed development and achieved ton-scale mass production, with product quality gaining international recognition. It has become the preferred supplier for multiple leading pharmaceutical companies.

As a "National High-tech Enterprise" , a "Up-scale Enterprise" and a "Hefei's Specialized and Sophisticated SMEs", Hefei Huana Biomedical Technology Co. Ltd. carries significant national missions. It is not only a key implementation unit for major projects under the the "National 13th Five-Year Plan", but its technological system has also been incorporated into the implementation plan for the "domestic technical support part of nucleic acid and dye technology" project. The company has established a patent portfolio centered on nucleic acid and dye technologies, having filed a total of 24 patent applications, with 19 already granted. These solid innovative achievements have been directly included as part of the domestic technological support in the national key science and technology special project, marking the company's continuous advancement towards the high end of the industrial value chain.

三、Core Team: 

Elite Academic Background with Deep Industry-Academia-Research Integration.

Hefei Huana Biomedical Technology Co. Ltd. has assembled a team of research talents from top-tier institutions both in China and abroad, including the Chinese Academy of Sciences, Peking University, Tsinghua University, Harvard University, and Stanford University. Key members of the core team include:

•   Dr. Zhangjie Shi (Chairman): A Chang Jiang Scholar Distinguished Professor and recipient of the National Natural Science Award. Formerly affiliated with Harvard University and Fudan University, he has extensive expertise in organic chemistry and nucleic acid chemistry.

• Dr. Zhaobo Gao (General Manager): An EMBA graduate of  China Europe International Business School. Previously served as a Senior Global Scientist and Project Director at Novartis, bringing rich experience in multinational pharmaceutical management and industrialization.

• Dr. Chengdong Wang, Dr. Qing Wu, and other key R&D personnel, possess profound expertise in nucleic acid modification, delivery systems, process scale-up, and related fields.

四、Technical System: 

From Foundational Innovation to Industrial Application.

Hefei Huana Biomedical Technology Co. Ltd. has established a full-chain technical system spanning from molecular design to large-scale production, centered on the deep integration of "Four Core Modification Capabilities" and "Ten Technology Platforms".

1. Four Core Modification Capabilities: The Foundation of Molecular Design.

The company possesses underlying technologies for systematic and precise modifications at the nucleic acid molecular level:

Base Modification: Modulate stability and functionality, and enable artificial encoding.

Sugar Ring Modification: Enhance enzymatic stability and optimize spatial configuration.

Phosphate  Modification: Regulate charge and stability, influencing metabolism and delivery.

Oligo's Structure Modification: Design complex structures with specialized functions (e.g., aptamers).

2. Ten Technical Platforms: The Engine for Industrial Translation.

Guided by the core capabilities above, the company has built ten technology platforms that support product development from gram-scale R&D to ton-scale manufacturing: 

Polyphosphorylation, Base Modification, Sugar Ring Modification, Solid/Liquid-Phase Gene Synthesis, Fermentation/Enzymatic Synthesis, Directed Enzyme Evolution, Phosphoramidite, Delivery System,  Dye and Vector/Linker Platform.

These platforms ensure the company can efficiently and stably translate cutting-edge molecular designs into high-quality products meeting GMP standards, while also providing customized project services for clients.

五、Product Portfolio: 

Centered on Three Core Fields, Providing Comprehensive Solutions.

Hefei Huana Biomedical Technology Co. Ltd. strategically aligns its product development with three key areas—small nucleic acid drugs, gene diagnostics, and mRNA vaccines—building a full-chain, multi-scenario product portfolio.  

1. Core Raw Materials and Tools for Small Nucleic Acid Drugs.

Focused on supplying critical materials for the development and production of siRNA, ASO, and other therapies.  

Core Monomers: DNA/RNA phosphoramidites, 2′-F/OMe/MOE modified monomers, LNA/ENA locked nucleic acid monomers, PMO monomers.  

Delivery Systems: GalNAc clusters (L96, NAG series), various linkers and carriers.  

Synthesis Support:Full suite of Oligo synthesis reagents (Ultra-Dry Acetonitrile, Activators, Oxidizing agent, etc.), specialty phosphorus reagents.  

2. Core Raw Materials and Delivery Systems for mRNA Vaccines. 

Providing a complete set of core materials for mRNA vaccines and therapeutics, spanning transcription, modification, and delivery.  

Cap Analogs (Cap): CleanCap® series (e.g., EGFP, Fluc, Cas9), traditional Cap structures (e.g., GAG, GGG).

Modified Nucleotides (NTP): NTP solutions, 5-Me-CTP, Pseudo-UTP, N1-Me-Pseudo-UTP, and others.  

Lipid Nanoparticles (LNP): Clinically validated lipids including SM-102, DLin-MC3-DMA, ALC-0315, DOTAP, DOTMA, DOPE, and more.

 3. Core Reagents and Raw Materials for Genetic Diagnostics.

Providing high-performance raw materials for molecular diagnostic technologies such as PCR, qPCR, sequencing, and fluorescent detection.

Nucleotide Substrates: High-purity dNTPs/dUTPs, modified and labeled nucleotides (e.g., Biotin-dUTP).

Fluorescent Detection Systems: A complete series of fluorescent dyes and their succinimidyl esters (SE), including FAM, TAMRA, ROX, Cy3, Cy5, Cy7, and others.

六、Production Capacity & Quality System: 

High Standards, Strong Compliance, Reliable Supply.

The company operates a modern production base with a total floor area exceeding 60,000 m². It is equipped with 4 standardized workshops, 58 reactor systems, and a Distributed Control System (DCS) for central control. The facility boasts an annual production capacity of over 8,000 liters of dNTPs and more than 60 metric tons of phosphoramidites.

Quality is the lifeline of the enterprise. Hefei Huana Biomedical Technology Co. Ltd. has established a rigorous quality management system aligned with ICH, PIC/S, and GMP guidelines. The company is ISO 9001 certified and has successfully passed stringent audits conducted by multiple leading domestic and international enterprises. Through meticulous management, documented in 1 quality manual, 545 procedural documents, and 347 operational standard documents, the company ensures full process control from raw materials to finished products, striving to achieve a 100% customer satisfaction rate.

七、Core Competitiveness: 
Focus on Upstream, In-depth Service, and Supply Chain Security.

No Downstream Competition: Focus exclusively on upstream raw and auxiliary materials, do not engage in downstream finished product development, thereby safeguarding all clients' interests.

Comprehensive Process and Impurity Characterization: Provide complete chromatographic analysis covering all known and potential impurities, along with reference standards and stringent control strategies, ensuring product purity and safety at the molecular level.

Rapid Response and Stable Supply: The company's in-house factory and deep supply chain management enable the company to support ton-scale orders and ensure fast delivery.

Stringent Intellectual Property Protection: The company has established a corporate confidentiality committee, a robust IP management system, and physical security measures.

八、VIII. Corporate Ethos: 
Diagnose Genes, Cure the Future

Vision: Diagnosis & Cure.

Mission: To pursue excellence in development and become a respected enterprise. Enabling the development of RNAi drugs, vaccines and diagnostic industries.

Core Values: Team First, Technology Driven, Customer Centric, Company Interests Foremost.

Corporate Spirit: Uphold Integrity and Self-Discipline, Champion Responsibility and Honesty, Strive with Dedication and Drive, Excel with Professionalism and Efficiency, Pioneer through Exploration and Innovation, Succeed through Collaboration and Mutual Benefit.

With solid R&D expertise, scalable production capacity, a rigorous quality system, and a clear cultural vision, Hefei Huana Biomedical Technology Co. Ltd. is steadily growing into a trusted strategic partner for core raw materials in the global nucleic acid industry. Moving forward, the company will continue to deepen its mastery of nucleic acid technologies, strengthen collaboration across the industrial chain, and empower customers to achieve their goals & value faster, better, and stronger with high‑quality products and services.